03Jan/13

Heart Metabolics Receives Funding for US Clinical Development of Heart … – PharmaLive (press release) (subscription)

Heart Metabolics Receives Funding for US Clinical Development of Heart
PharmaLive (press release) (subscription)
The proceeds of the Series A round will be used to advance U.S. clinical development of the company’s lead drug candidate, perhexiline, for the treatment of heart failure symptoms in patients with hypertrophic cardiomyopathy (“HCM”). Investors in the

and more »

03Jan/13

Heart Metabolics Receives Funding for US Clinical Development of Heart … – PharmaLive.com (press release)

Heart Metabolics Receives Funding for US Clinical Development of Heart
PharmaLive.com (press release)
The proceeds of the Series A round will be used to advance U.S. clinical development of the company’s lead drug candidate, perhexiline, for the treatment of heart failure symptoms in patients with hypertrophic cardiomyopathy (“HCM”). Investors in the

and more »

03Jan/13

Heart Metabolics Receives Funding for U.S. Clinical Development of Heart … – PR Newswire (press release)

Heart Metabolics Receives Funding for U.S. Clinical Development of Heart
PR Newswire (press release)
The proceeds of the Series A round will be used to advance U.S. clinical development of the company’s lead drug candidate, perhexiline, for the treatment of heart failure symptoms in patients with hypertrophic cardiomyopathy (“HCM”). Investors in the

and more »

03Jan/13

Veloxis' Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients … – GlobeNewswire (press release)

Veloxis’ Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients
GlobeNewswire (press release)
Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up. Results of this trial demonstrated that patients can be successfully

and more »